


## SBI-115

Cat. No.:	HY-111534		
CAS No.:	882366-16-7		
Molecular Formula:	C <sub>14</sub> H <sub>13</sub> ClN <sub>2</sub> O <sub>4</sub> S		
Molecular Weight:	341		
Target:	G protein-coupled Bile Acid Receptor 1		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 150 mg/mL (439.88 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.9326 mL	14.6628 mL	29.3255 mL
		5 mM	0.5865 mL	2.9326 mL	5.8651 mL
10 mM		0.2933 mL	1.4663 mL	2.9326 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> <li>Add each solvent one by one: corn oil Solubility: 5 mg/mL (14.66 mM); Suspended solution; Need ultrasonic</li> <li>Add each solvent one by one: 2% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 53% saline Solubility: 3 mg/mL (8.80 mM); Suspended solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (7.33 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (7.33 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

Description	SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 <sup>[1]</sup> .
In Vitro	SBI-115 (100-200 μM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Tauro lithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes <sup>[1]</sup> .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Cell Proliferation Assay<sup>[1]</sup>

Cell Line:	shRNA-transfected ADPKD cholangiocytes
Concentration:	100, 200 $\mu$ M
Incubation Time:	24 hours
Result:	Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocytes with TLCA.

## CUSTOMER VALIDATION

- Nat Commun. 2022 Oct 14;13(1):6081.
- Acta Pharm Sin B. 21 July 2021.
- Pharmacol Res. 2022 Sep 21;106459.
- NPJ Biofilms Microbiomes. 2023 Feb 8;9(1):8.
- Phytomedicine. 2023 Jul 22;119:154982.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Masyuk TV, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gas signaling. Hepatology. 2017 Oct; 66(4):1197-1218.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA